Glioma peptide vaccine - immatics/BioNTech

Drug Profile

Glioma peptide vaccine - immatics/BioNTech

Alternative Names: Actively personalized vaccines (APVACs); APVAC1; APVAC1-peptide-vaccine; APVAC2; APVAC2-peptide-vaccine

Latest Information Update: 05 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glioma Actively Personalized Vaccine Consortium
  • Developer BioNTech; immatics biotechnologies GmbH
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma

Most Recent Events

  • 05 Jul 2018 Immatics completes a phase I trial for Glioblastoma (Adjunctive treatment, Combination therapy, Early-stage disease) in Germany, Switzerland, United Kingdom, Spain, Netherlands, Denmark and USA (Intradermal) (NCT02149225)
  • 01 Jun 2018 Adverse events, efficay and immunogenicity data from a phase I trial in Glioblastoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 16 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top